Yaron Werber, Biotechnology Analyst, interviewed management teams from four biotech companies about opportunities, challenges, and the reimbursement outlook when launching innovative therapies for oncology & immunology. They discuss the importance of innovation and differentiation when launching new products, global drug pricing, and the looming impact of the Inflation Reduction Act.
Murdo Gordon, Executive VP Global Commercial Operations, Amgen
Keith Woods, COO, Argenx
Josh Neiman, SVP, Chief Commercial Officer – North America & Europe, Beigene
Ying Huang, Ph.D., CEO, Legend Biotech
Get the Full Report
If you’re already a member of our Research portal, log in.Log In
If not, reach out to us directly for more information.